Abstract: A ferrocene derivative of formula (I). In formula (I), Z is selected from O, NH and S; R1 is selected from hydrogen, methyl and halogen; each R2 is independently selected from hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy and nitro; and n is an integer from 0 to 5. The ferrocene derivative, a salt thereof, as well as a solvate thereof have anti-tumor activity, and can be used as candidate drugs or lead compounds for treating diseases such as tumors and cancer.

Abstract: A complex salt formed from a compound of formula (I) and an alkaloid, a preparation method therefor and use thereof are provided. In particular, a complex salt formed from rupestonic acid and matrine, oxymatrine, sophocarpine and sophoridine, or a composition thereof, has potential efficacy in treating a tumor/cancer or preparing related medicaments.

Abstract: A method for preparing a NdFeB permanent magnetic material may include providing a covered NdFeB magnetic powder by depositing heavy rare earth particles or high-melting particles onto a NdFeB magnetic powder by physical vapor deposition; and performing orientation molding and sintering on the covered NdFeB magnetic powder to provide the NdFeB permanent magnetic material.

Abstract: A method for preparing a NdFeB permanent magnetic material may include providing a covered NdFeB magnetic powder by depositing heavy rare earth particles or high-melting particles onto a NdFeB magnetic powder by physical vapor deposition; and performing orientation molding and sintering on the covered NdFeB magnetic powder to provide the NdFeB permanent magnetic material.

Abstract: A nicotinic acid derivative is represented by formula (I), and a pharmaceutically acceptable salt or solvate thereof. In formula (I), Z is selected from O, S, NR3, wherein R3 is hydrogen or C1-6 alkyl. R1 or R2 is independently selected from the group consisting of hydrogen, C1-6 alkyl, C1-6 alkoxy, halo C1-6 alkyl, halogen, cyano, nitro, aryl, aryloxy, heteroaryl, heteroaryloxy, heterocyclyl, and heterocyclyloxy. Such C1-6 alkyl, C1-6 alkoxy, halo C1-6 alkyl, aryl, heteroaryl, and heterocyclyl may be optionally substituted with a substituent selected from the group consisting of C1-6 alkyl, C1-6 alkoxy, halo C1-6 alkyl, halogen, cyano, nitro, and aryl. These compounds or salts thereof have a strong inhibitory activity on colorectal cancer cell line HCT-116, human lung cancer cell line A549, and breast cancer cell line MCF-7.

Abstract: A method for recovering thorium and rare earth elements from rare earth waste residues includes the steps of (1) mixing rare earth waste residues with an inorganic acid and heating to obtain a stock solution containing thorium and rare earth elements; (2) extracting thorium and rare earth elements from the stock solution with an organic phase containing an extractant; (3) washing the organic phase obtained after extraction in step (2) with a washing solution to move rare earth elements into the aqueous phase and leave thorium in the organic phase; (4) back-extracting the organic phase containing thorium obtained in step (3) with a back-extraction solution to extract move thorium in the organic phase into the aqueous phase. The extractant contains alkyl phosphonic acid monoalkyl ester and dialkylphosphinic acid.

Abstract: An extractant and a method for the extraction and separation of yttrium are disclosed in the invention. Cations of said extractant are selected from the group of quaternary phosphonium or quaternary ammonium, and the anion is sec-octylphenoxy acetate. The extractant has a simple composition, the formulated organic phase has stable properties and can be recycling used without significantly decreased concentration. The present invention used a mixed organic phase consisting of an extractant and a diluent to extract a rare earth feed liquid containing yttrium, and then washed and back extracted it with deionized water so that the consumption of acid and alkali in all the processes of extraction, washing and back extraction was avoided. Therefore, the extraction is carried out under a low acidity and a high extraction efficiency was ensured. The organic phase can be recycling used without saponification, so that no ammonia wastewater was produced in the processes.

Abstract: The present invention relates to the ferrocene derivative represented by formula (IA) or formula (IB), or to the pharmaceutically acceptable salt or solvate thereof and to the pharmaceutical composition thereof. Wherein, R is independently selected from H, halogen, cyano, nitro, C1-C6 alkyl, C1-C6 alkoxy, hydroxy-C1-C6 alkyl, halo-C1-C6 alkyl, halo-C1-C6 alkoxy or C1-C6 alkoxy-C1-C6 alkoxy; Z is selected from O, S or NR1, wherein R1 is independently H or C1-C6 alkyl; n is an integer from 0 to 5. The present invention also provides a method and the pharmaceutical application thereof for preparing the compounds represented by formula (IA) or formula (IB) or the pharmaceutically acceptable salts thereof. The compounds have a strong inhibitory activity against human lung cancer cell line A549, colorectal cancer cell line HCT116 and/or breast cancer cell line MCF-7.